| http://www.w3.org/ns/prov#value | - This press release includes forward-looking statements regarding Isis??? collaboration with Genzyme, a Sanofi company, and the development, activity, therapeutic benefit, safety and commercial potential of KYNAMRO in treating patients with homozygous FH. Any statement describing Isis??? goals, expectations, financial or other projections, intentions or beliefs, including the planned commercializat
|
